To read the full story
Related Article
- Lucentis, Rituxan Biosimilars Win Label Expansions
September 28, 2023
- 1st Lucentis Biosimilar Launched in Japan, Senju Eyes 6.9 Billion Yen in 5th Year
December 10, 2021
- With First Ophthalmologic Biosimilar Set to Debut, Specialist Says Close Attention Required for Unexpected Side Effects
December 9, 2021
- 1st Lucentis Biosimilar, 3rd Humira Follow-On Get Japan Listing
November 24, 2021
- Senju Gearing Up to Grow Lucentis Biosimilar into Its Mainstay Product
November 1, 2021
- Lucentis Biosimilar Filed in Japan; Senju/Gene Techno Eye 2021 Approval
September 23, 2020
- Gene Techno CEO Eyes Lucentis Biosimilar Launch in November 2021, Expects Share of “At Least 30%”
April 23, 2020
BUSINESS
- Shionogi, Cilcare Ink Research Collab on Novel Hearing Loss Drugs
May 12, 2025
- Canaglu Now Available in Thailand: Mitsubishi Tanabe
May 12, 2025
- Keytruda Tops Japan Drug Sales Ranking for 19th Month: Encise
May 12, 2025
- Japan Ethical Drug Sales Up 5.2% in March: Crecon
May 12, 2025
- Otsuka, Keio Join Hands to Facilitate “Social Implementation” of Psychedelics
May 12, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…